ASCELIA PHARMA

Share ticker: ACE
Nasdaq Stockholm (small cap)

ASCELIA PHARMA

ADVANCING ORPHAN ONCOLOGY

Pareto Securities Health Care Conference

2 September 2020

FORWARD LOOKING STATEMENTS

This presentation, which includes all information and data on the following slides, any oral statements made when presenting these slides, and any other material distributed or statements made at, or in connection with, such presentation (the "Presentation"), relates to Ascelia Pharma AB (publ) (hereinafter, together with its subsidiaries, the "Company") is furnished to you solely for your information and may not be reproduced or redistributed, in whole or in part, to any other person without the prior written consent of the Company. You should not rely upon it or use it to form the definitive basis for any decision, contract, commitment or action whatsoever, with respect to any transaction or otherwise.

The information included in this Presentation may contain certain forward-looking statements relating to the business, financial performance and results of the Company and/or the industry in which it operates. Forward-looking statements concern future circumstances and results and other statements that are not historical facts, sometimes identified by the words "believes", "expects", "predicts", "intends", "projects", "plans", "estimates", "aims", "foresees", "anticipates", "targets", and similar expressions. The forward-looking statements contained in this Presentation, including assumptions, opinions and views of the Company or cited from third party sources are solely opinions and forecasts which are subject to risks, uncertainties and other factors that may cause actual events to differ materially from any anticipated development. Neither the Company nor any of its affiliates, directors, employees or advisors provides any assurance that the assumptions underlying such forward-looking statements are free from errors nor do any of them accept any responsibility for the future accuracy of the opinions expressed in this Presentation or the actual occurrence of the forecasted developments. This Presentation speaks as of the applicable reporting date, and there may have been changes in matters which affect the Company subsequent to the date of this Presentation. Neither the issue nor delivery of this Presentation shall under any circumstance create any implication that the information contained herein is correct as of any time subsequent to the date hereof or that the affairs of the Company have not since changed, and the Company does not intend, and does not assume any obligation, to update or correct any information included in this Presentation.

Each person should make their own independent assessment of the merits of the Company and should consult their own professional advisors. By receiving this Presentation, you acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own opinion of the potential future performance of the Company's business.

ASCELIA PHARMA

ASCELIA PHARMA: ADVANCING ORPHAN ONCOLOGY

A global health burden

44 million people live with cancer; 18 million are diagnosed each year[1]

USD 150 bn spent yearly on cancer therapies alone[2]

Orphan drugs represent 12 of 15 new active substances in oncology launched in the US in 2018[2]

Dedicated to unmet needs in orphan oncology

Drugs with a clear development and market pathway

- **Advancing liver imaging** with orphan MRI contrast agent with no competition (in ongoing Phase 3)
- **Advancing chemotherapy** with novel tablet for gastric cancer (Phase 2 ready)

Capabilities to bring new compounds to market

- World class cross-functional team
- Headquartered in Malmö, Sweden
- Listed on NASDAQ STOCKHOLM in 2019 (ticker: ACE)
- Solid financial position with SEK 239 million in liquid assets in early July 2020

Sources
1) https://canceratlas.cancer.org/the-burden/the-burden-of-cancer/ (2018 figures)
2) Global Oncology Trends 2019, IQVIA (2018 figures)

ASCELIA PHARMA

CLINICAL STAGE PORTFOLIO ADDRESSING CLEAR UNMET NEEDS

Drug candidate	Indication	Phase 1	Phase 2	Phase 3	Filing	Launch
Mangoral • Only non-gadolinium imaging drug • No competing drugs • $350-500M market with upside potential • De-risked Phase 3 clinical program • Orphan Drug Designation	**Visualization of focal liver lesions** • Liver metastases • Primary liver cancer • Benign lesions	✓	✓	2020 – H2-2021	H1-2022	Q4-2022 – H1-2023
Oncoral • Novel tablet chemotherapy formulation • Phase 1 completed with promising results • Gastric cancer is an Orphan indication	**Treatment of gastric cancer**	✓	2021 – 2023	Strong case for development and commercialization partnering after Phase 2		

ASCELIA PHARMA

STRONG AND EXPERIENCED MANAGEMENT AND BOARD

EXECUTIVE MANAGEMENT

Magnus Corfitzen
Chief Executive Officer

Kristian Borbos
Chief Financial Officer

Carl Bjartmar, MD, Ph.D
Chief Medical Officer

Julie Waras Brogren
Chief Commercial Officer

Mikael Widell
Head of IR and Communications

BOARD OF DIRECTORS

Peter Benson
Chairman

Lauren Barnes
Director

Bo Jesper Hansen, MD, Ph.D
Director

Hans Maier, Ph.D, Prof.
Director

Helena Wennerström
Director

Niels Mengel
Director

René Spogård
Director

SIGNIFICANT PROGRESS IN 2020 DESPITE COVID-19

February
First patient in Mangoral Phase 3 study SPARKLE

April
Oncoral patent approved in Japan

May
First participant in Mangoral hepatic study

June
Directed share issue to fund Mangoral commercial preparations

ASCELIA PHARMA

MANGORAL

LIVER IMAGING DRUG
IN PHASE 3 CLINICAL STUDIES

ASCELIA PHARMA

LIVER METASTASES: HOW TO FIND AND WHAT TO DO

DETECT AND LOCALISE

Liver MRI is the **most sensitive** method for detection of liver metastases[2)]

Gadolinium based imaging drugs are given to maximise accuracy of liver metastasis detection in MRI

TREAT

Treatment options for liver metastases are:

- Surgical resection (only if detected early)
- Localised therapies (ablation embolisation, radiation)
- Drug therapy

IMPROVE SURVIVAL

Accurate, early detection of liver metastases significantly impact treatment decisions and patient survival



1) Guy diSibio and Samuel W. French (*2008*) Metastatic Patterns of Cancers: Results From a Large Autopsy Study. Archives of Pathology & Laboratory Medicine: June 2008, Vol. 132, No. 6, pp. 931-939
2) Albiin N et al. Manganese chloride tetrahydrate (CMC-001) enhanced liver MRI: evaluation of efficacy and safety in healthy volunteers. MAGMA. 2012 Mar 8
3) Clinical Colorectal Cancer, Vol. 15, No. 4, Dec 2016, e183-192

ASCELIA PHARMA

MANGORAL – MANGANESE BASED LIVER CONTRAST AGENT

TODAY

NORMAL KIDNEY FUNCTION
Gadolinium imaging drug

POOR KIDNEY FUNCTION
NO imaging drug due to potentially deadly side-effects (black-box warning)

WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF)

See full prescribing information for complete boxed warning.

Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs. Avoid use of GBCAs in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities.

- **The risk for NSF appears highest among patients with:**
  - **Chronic, severe kidney disease (GFR < 30 mL/min/1.73m^2), or**
  - **Acute kidney injury.**
- **Screen patients for acute kidney injury and other conditions that may reduce renal function.**
- **For patients at risk for chronically reduced renal function (for example, age >60 years, hypertension or diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing (5.1).**

TOMORROW

NORMAL KIDNEY FUNCTION
Gadolinium imaging drug

POOR KIDNEY FUNCTION
3-4% of patients
MANGORAL imaging drug
(based on manganese)

Mangoral aims to be the only standard of care liver MRI imaging drug for patients with impaired kidney function

280,000
patients with impaired kidney function in major markets

ASCELIA PHARMA

MANGORAL MAKES A REAL DIFFERENCE

PATIENT EXAMPLE FROM PHASE II STUDY



Unenhanced liver MRI

(standard of care today in target patient population)



Mangoral enhanced liver MRI

Liver metastasis appear with Mangoral

Source: Patient with colorectal cancer. (Study CMC-P002)

DE-RISKED PHASE 3 STUDY

Strong data package for Mangoral

Six phase 1 and 2 clinical studies completed

Consistent strong efficacy readout and safety profile

Blind read study of all imaging data presented at major conferences

- The study with 178 persons further underlined that Mangoral significantly improves MRI performance
- 33% more lesions were detected after Mangoral enhanced MRI
- **Mangoral significantly improved lesion visualisation**
  Delineation: p-value <0.0001
  Conspicuity: p-value <0.0001

Phase 3 registration-enabling study (study ongoing)

Number of patients	Global study in up to 200 patients
Endpoint	**Lesion visualization** • Lesion border delineation (border sharpness of lesions) • Conspicuity (lesion contrast compared to liver background)
Comparator	Unenhanced MRI + Mangoral MRI *vs.* Unenhanced MRI
Follow-up	72 hours
Randomisation	**No** – each patient at his/her own control
Validation	Phase 3 program has been discussed with FDA and EMA

ASCELIA PHARMA

MANGORAL

PREPARING FOR COMMERCIALIZATION

ASCELIA PHARMA

MANGORAL IS THE ONLY PRODUCT IN A $350-500M MARKET

Addressable market

8.5 million people	… in key markets have suspected liver metastases or primary liver cancer (based on relevant primary cancers, colorectal, breast, lung and gastric)
280,000 of these	… equivalent to 3-4% have poor kidney function (stage 5, 4 or 3 worsening or acute kidney injury – with higher prevalence in elderly and cancer populations)
need MRI	… for diagnosis, monitoring and surveillance
at $1,500 - 3,000 per dose	… based on unmet needs in patient population and value of contrast enhanced MRI
$350–500 million	**… addressable market annually with no competing drug**

ASCELIA PHARMA

COMMERCIAL PREPRATIONS IN PROGRESS

PREPARE THE PRODUCT | **PREPARE THE MARKET** | **PREPARE THE LAUNCH**

2020 | **2021** | **2022**

H1-2020
ADVANCE COMMERCIAL STRATEGIES

- ✓ Pre-launch plans & decision points
- ✓ Product positioning & targeting
- ✓ Pricing & access insights

H2-2020
PROGRESS GO-TO-MARKET BLUEPRINT

- Detail US operations blueprint & rest of world partnering plan
- Advance market sizing & roll-out priorities
- Advance dialogue with payers & clinical decision makers

ASCELIA PHARMA

OUTLOOK FOR MARKET OPTIMAL LAUNCH STRATEGY

Strong case for own US commercialization

US operations

- Field team of 10-20 FTEs can reach 3,500-5,000 healthcare professionals
- Target major hospitals with nephrology units and independent specialist clinics
- US capability to include commercial and cross-functional support team
- Local logistics and distribution partnerships

Optimal RoW uptake with partnering



Europe, Japan and RoW

- Roll-out according to market potential, pricing and access
- Leverage global synergies in pre-launch and launch
- Ascelia Pharma vs. partner roles evaluated to maximize value

ONCORAL

CHEMOTHERAPY TABLET FOR GASTRIC CANCER
READY FOR PHASE 2

ASCELIA PHARMA

ONCORAL – NOVEL IRINOTECAN TABLET READY FOR PHASE 2

NOVEL ORAL PATENTED FORMULATION

- Formulated as a **tablet** for convenient dosing and health-economic benefits
- **Promising safety potential** of oral administration
- Potential for **all-tablet chemo-combination**

PHARMACEAUTICAL INGRIEDIENT HAS PROVEN EFFECT

- Irinotecan shown to be effective in **killing cancer cells**
- Expected to be efficacious and safe **together** with other well-recognized anti-cancer drugs
- **Orphan drug indication** for gastric cancer by the FDA and EMA

With promising Phase 1 results, we are now preparing for Phase 2

ASCELIA PHARMA

TARGETING >$4 BILLION MARKET IN GASTRIC CANCER

DISEASE CHARACTERISTICS

- Gastric cancer is the 6th most prevalent cancer in the world[1)]
- Gastric cancer is the 3rd most frequent cause of cancer death[1)]
- The 5-year survival of gastric cancer is approximately 20%[2)]

MARKET OPPORTUNITY

- Market for gastric cancer treatment forecast to increase to >$ 4 billion in 2024[3)]
- Drug treatment typically combination of 2-3 drugs

Key growth drivers

1. Increase in overall incidence of gastric cancer
2. Anticipated increase in treatment rates
3. Extended treatment duration
4. New lines of more expensive therapies
5. Increased number of patients receiving branded therapy

1) IARC (2012)
2) Clinical Colorectal Cancer 2015; 14(4): 239-50
3) GlobalData - Gastric and Gastroesophageal Junction Adenocarcinoma – Global Drug Forecast and Market Analysis to 2024

ASCELIA PHARMA

PRIORITIES 2020 AND INVESMENT HIGHLIGHTS

ASCELIA PHARMA

Priorities in H2-2020



ASCELIA PHARMA

ASCELIA PHARMA IN SUMMARY

Ascelia Pharma (ticker: ACE) – Advancing orphan oncology

- Drugs targeting unmet medical needs with a clear development and market pathway
- Solid financial position with SEK 239 million in cash in beginning of July 2020

Mangoral – Phase 3 non-gadolinium liver imaging drug

- $350-500 million annual addressable market
- No competing drugs
- Ongoing Phase 3 program with high likelihood of success – study results expected in H2-2021
- Orphan Drug Designation

Oncoral – Phase 2 ready oral chemotherapy for gastric cancer

- Novel tablet formulation with significant patient and hospital benefits
- Effective molecule for killing cancer
- Promising Phase 1 results and preparing for Phase 2

ASCELIA PHARMA

ASCELIA PHARMA

Share ticker: ACE
Nasdaq Stockholm (small cap)

Q&A

www.ascelia.com

Follow us on LinkedIn